Cefotaxime sodium is the sodium salt form of cefotaxime, a beta-lactam, third-generation cephalosporin antibiotic with bactericidal activity. Cefotaxime sodium binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. Inactivation of PBPs interferes with the cross-linking of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis. Compared to the second and first generation cephalosporins, cefotaxime sodium is more active against gram-negative bacteria and less active against gram-positive bacteria.

This report contains market size and forecasts of Cefotaxime Sodium API in Germany, including the following market information:

Germany Cefotaxime Sodium API Market Revenue, 2015-2020, 2021-2026, ($ millions)

Germany Cefotaxime Sodium API Market Consumption, 2015-2020, 2021-2026, (MT)

Germany Cefotaxime Sodium API Production Capacity, 2015-2020, 2021-2026, (MT)

Top Five Competitors in Germany Cefotaxime Sodium API Market 2019 (%)

The global Cefotaxime Sodium API market was valued at 105.2 million in 2019 and is projected to reach US$ 102 million by 2026, at a CAGR of -0.8% during the forecast period. While the Cefotaxime Sodium API market size in Germany was US$ XX million in 2019, and it is expected to reach US$ XX million by the end of 2026, with a CAGR of XX% during 2020-2026.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Cefotaxime Sodium API manufacturers, suppliers, distributors and industry experts on the impacts of the COVID-19 pandemic on businesses, with top challenges including ingredients and raw material delays, component and packaging shortages, reduced/cancelled orders from clients and consumers, and closures of production lines in some impacted areas.

This report also analyses and evaluates the COVID-19 impact on Cefotaxime Sodium API production and consumption in Germany


Total Market by Segment:

Germany Cefotaxime Sodium API Market, By Type, 2015-2020, 2021-2026 ($ millions) & (MT)

Germany Cefotaxime Sodium API Market Segment Percentages, By Type, 2019 (%)

ChP

USP

EP

Chp refers to Chinese Pharmacopoeia. USP refers to the United States Pharmacopeia. EP refers to the European Pharmacopoeia. And the proportion of ChP in 2019 is about 77.92%.

Germany Cefotaxime Sodium API Market, By Application, 2015-2020, 2021-2026 ($ millions) & (MT)

Germany Cefotaxime Sodium API Market Segment Percentages, By Application, 2019 (%)

Single Injection

Compound Injection

Cefotaxime sodium API is widely for single injection and compound injection. The proportion of single injection in 2019 is about 76.02%.


Competitor Analysis

The report also provides analysis of leading market participants including:

Total Cefotaxime Sodium API Market Competitors Revenues in Germany, by Players 2015-2020 (Estimated), ($ millions)

Total Cefotaxime Sodium API Market Competitors Revenues Share in Germany, by Players 2019 (%)

Total Germany Cefotaxime Sodium API Market Competitors Sales, by Players 2015-2020 (Estimated), (MT)

Total Germany Cefotaxime Sodium API Market Competitors Sales Market Share by Players 2019 ($ millions)


Further, the report presents profiles of competitors in the market, including the following:

REYOUNG

Nectar Lifesciences

Medya Pharma

Sandoz

Kelun

NCPC

Aurobindo Pharma

United Laboratories

Orchid Pharma

CSPC

Kopran

Covalent

ACS Dobfar

Dawnrays